Literature DB >> 17972035

Homocysteine and leukoaraiosis: time for a clinical trial?

S Sacco, A Carolei.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17972035     DOI： 10.1007/s10072-007-0827-8

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  25 in total

Review 1.  Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies.

Authors:  Earl S Ford; S Jay Smith; Donna F Stroup; Karen K Steinberg; Patricia W Mueller; Stephen B Thacker
Journal:  Int J Epidemiol       Date:  2002-02       Impact factor: 7.196

2.  Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area.

Authors:  J D Spence; M R Malinow; P A Barnett; A J Marian; D Freeman; R A Hegele
Journal:  Stroke       Date:  1999-05       Impact factor: 7.914

3.  Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity.

Authors:  I I Kruman; C Culmsee; S L Chan; Y Kruman; Z Guo; L Penix; M P Mattson
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

4.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

Authors: 
Journal:  JAMA       Date:  2002 Oct 23-30       Impact factor: 56.272

5.  Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke.

Authors:  J W Eikelboom; G J Hankey; S S Anand; E Lofthouse; N Staples; R I Baker
Journal:  Stroke       Date:  2000-05       Impact factor: 7.914

6.  Homocysteine lowering with folic acid and B vitamins in vascular disease.

Authors:  Eva Lonn; Salim Yusuf; Malcolm J Arnold; Patrick Sheridan; Janice Pogue; Mary Micks; Matthew J McQueen; Jeffrey Probstfield; George Fodor; Claes Held; Jacques Genest
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

7.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Authors:  James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

8.  Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS)

Authors:  B M McQuillan; J P Beilby; M Nidorf; P L Thompson; J Hung
Journal:  Circulation       Date:  1999-05-11       Impact factor: 29.690

9.  Plasma homocysteine and severe white matter disease.

Authors:  B Censori; T Partziguian; O Manara; M Poloni
Journal:  Neurol Sci       Date:  2007-10-31       Impact factor: 3.307

10.  Homocysteine and stroke: evidence on a causal link from mendelian randomisation.

Authors:  Juan P Casas; Leonelo E Bautista; Liam Smeeth; Pankaj Sharma; Aroon D Hingorani
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.